Impact of COVID-19 on Patients With Psoriasis or Psoriatic Arthritis

Philip J Mease; Peter Nash; Suzanne Grieb; Vinod Chandran

doi:10.3899/jrheum.2023-0521

Impact of COVID-19 on Patients With Psoriasis or Psoriatic Arthritis

J Rheumatol. 2023 Nov;50(Suppl 2):27-30. doi: 10.3899/jrheum.2023-0521. Epub 2023 Aug 1.

Authors

Philip J Mease¹, Peter Nash², Suzanne Grieb³, Vinod Chandran⁴

Affiliations

¹ P.J. Mease, MD, Swedish Medical Center/Providence St. Joseph Health, and University of Washington School of Medicine, Seattle, Washington, USA.
² P. Nash, MBBS, School of Medicine, Griffith University, Nathan, Queensland, Australia.
³ S. Grieb, PhD, MSPH, Patient Research Partner, New York, New York, USA.
⁴ V. Chandran, MBBS, MD, DM, PhD, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, and Division of Rheumatology, Department of Medicine, Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. [email protected].

PMID: 37527863
DOI: 10.3899/jrheum.2023-0521

Abstract

Given the impact of the coronavirus disease 2019 (COVID-19) on patients with psoriatic disease (PsD), a session was devoted at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2022 annual meeting to discussing the current understanding of the risk of severe COVID-19 in patients with PsD. The effects of PsD and its treatment on prevention and treatment of COVID-19 with vaccinations, antiviral drugs, and monoclonal antibodies were discussed. The session concluded with a presentation on the perspectives of patient research partners about their experiences with COVID-19.

Keywords: COVID-19; GRAPPA; arthritis; psoriasis; psoriatic; vaccines.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Arthritis, Psoriatic* / complications
Arthritis, Psoriatic* / drug therapy
COVID-19*
Dermatology*
Humans
Psoriasis* / complications
Psoriasis* / drug therapy
Rheumatology*